Literature DB >> 9536270

Transduction of human macrophages using a stable HIV-1/HIV-2-derived gene delivery system.

P Corbeau1, G Kraus, F Wong-Staal.   

Abstract

We have previously established a stable HIV-1 packaging cell line, psi 422, which yielded high titers of an HIV-1 vector capable of efficiently transducing CD4+ cells. In order to increase the safety of this gene delivery system, we have now replaced the HIV-1 vector with an HIV-2 vector to abolish any risk of homologous recombination between the packaging cells and the vector. The HIV-2 vector was also modified by insertion of a cis-acting constitutive transport element which confers Rev independence. The supernatant of psi 422 cells stably transfected with this new vector was capable of transducing CD4+ cells with a titer of 10(4) transducing units per milliliter. This result shows that cross-packaging of HIV-2 vectors with the HIV-1 packaging cells is quite efficient. Using this new stable HIV-1/HIV-2 gene delivery system, we were able to transduce human monocyte-derived primary macrophages, which are refractory to murine retrovirus-mediated transduction. The availability of a stable HIV-based gene delivery system for macrophages, a key target cell in HIV infection; is an important advance in gene therapy for AIDS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9536270     DOI: 10.1038/sj.gt.3300563

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  10 in total

1.  An inducible human immunodeficiency virus type 1 (HIV-1) vector which effectively suppresses HIV-1 replication.

Authors:  D S An; K Morizono; Q X Li; S H Mao; S Lu; I S Chen
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

2.  Transduction of human progenitor hematopoietic stem cells by human immunodeficiency virus type 1-based vectors is cell cycle dependent.

Authors:  R E Sutton; M J Reitsma; N Uchida; P O Brown
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

3.  Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells.

Authors:  A A Bukovsky; J P Song; L Naldini
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

4.  Development of multigene and regulated lentivirus vectors.

Authors:  J Reiser; Z Lai; X Y Zhang; R O Brady
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  Lentivirus vectors using human and simian immunodeficiency virus elements.

Authors:  S M White; M Renda; N Y Nam; E Klimatcheva; Y Zhu; J Fisk; M Halterman; B J Rimel; H Federoff; S Pandya; J D Rosenblatt; V Planelles
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

6.  Heterologous human immunodeficiency virus type 1 lentiviral vectors packaging a simian immunodeficiency virus-derived genome display a specific postentry transduction defect in dendritic cells.

Authors:  Caroline Goujon; Loraine Jarrosson-Wuilleme; Jeanine Bernaud; Dominique Rigal; Jean-Luc Darlix; Andrea Cimarelli
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

7.  A third-generation lentivirus vector with a conditional packaging system.

Authors:  T Dull; R Zufferey; M Kelly; R J Mandel; M Nguyen; D Trono; L Naldini
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

8.  Dual-promoter lentiviral system allows inducible expression of noxious proteins in macrophages.

Authors:  Hui Pan; Gustavo Mostoslavsky; Evgeny Eruslanov; Darrell N Kotton; Igor Kramnik
Journal:  J Immunol Methods       Date:  2007-10-18       Impact factor: 2.303

9.  Evaluation of transduction efficiency in macrophage colony-stimulating factor differentiated human macrophages using HIV-1 based lentiviral vectors.

Authors:  Francisco J Leyva; Joshua J Anzinger; J Philip McCoy; Howard S Kruth
Journal:  BMC Biotechnol       Date:  2011-01-31       Impact factor: 2.563

10.  Substitution of the Rev-response element in an HIV-1-based gene delivery system with that of SIVmac239 allows efficient delivery of Rev M10 into T-lymphocytes.

Authors:  Narasimhachar Srinivasakumar
Journal:  AIDS Res Ther       Date:  2008-06-05       Impact factor: 2.250

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.